Portola Pharmaceuticals (PTLA) Set to Announce Quarterly Earnings on Wednesday

Share on StockTwits

Portola Pharmaceuticals (NASDAQ:PTLA) is set to announce its earnings results after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($1.05) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.02) EPS for the quarter, hitting the Zacks’ consensus estimate of ($1.02). The firm had revenue of $22.17 million during the quarter, compared to the consensus estimate of $20.60 million. Portola Pharmaceuticals had a negative return on equity of 238.48% and a negative net margin of 618.46%. The firm’s revenue was up 233.9% on a year-over-year basis. During the same period in the prior year, the business earned ($1.28) EPS. On average, analysts expect Portola Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of PTLA opened at $25.43 on Tuesday. The company has a market cap of $1.73 billion, a P/E ratio of -5.08 and a beta of 2.18. The stock’s fifty day moving average is $26.43. The company has a debt-to-equity ratio of 5.15, a quick ratio of 4.77 and a current ratio of 4.81. Portola Pharmaceuticals has a 12 month low of $14.81 and a 12 month high of $38.53.

A number of research analysts recently commented on PTLA shares. ValuEngine downgraded Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. BidaskClub downgraded Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 21st. Zacks Investment Research upgraded Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research note on Wednesday, July 17th. William Blair restated an “outperform” rating on shares of Portola Pharmaceuticals in a research note on Monday, June 17th. Finally, Cowen restated a “buy” rating on shares of Portola Pharmaceuticals in a research note on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $41.43.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.

Further Reading: How Does the Quiet Period Work?

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MFA FINL INC/SH  Set to Announce Quarterly Earnings on Wednesday
MFA FINL INC/SH Set to Announce Quarterly Earnings on Wednesday
PetIQ  Set to Announce Quarterly Earnings on Wednesday
PetIQ Set to Announce Quarterly Earnings on Wednesday
Portola Pharmaceuticals  Set to Announce Quarterly Earnings on Wednesday
Portola Pharmaceuticals Set to Announce Quarterly Earnings on Wednesday
Quintana Energy Services  to Release Earnings on Wednesday
Quintana Energy Services to Release Earnings on Wednesday
Stantec  Scheduled to Post Earnings on Wednesday
Stantec Scheduled to Post Earnings on Wednesday
Skyworks Solutions  to Release Quarterly Earnings on Wednesday
Skyworks Solutions to Release Quarterly Earnings on Wednesday


© 2006-2019 Ticker Report